Clinical trials: Hemostatic Disorders
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
This phase I multicenter feasibility trial is studying the safety and potential efficacy of infusing ex vivo expanded cord blood progenitors with one unmanipulated umbilical cord blood unit for transplantation following…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00343798
- Testing
- cyclophosphamide, fludarabine phosphate, cyclosporine
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL)
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells
- Conditions
- Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04488354
- Testing
- CLBR001 and SWI019
- Where
- 8 sites in United States
- Volunteers
- 16 people
- Sponsor
- Calibr, a division of Scripps Research
Multiple Myeloma and Plasma Cell Neoplasm
PAD. ICORG 05-01, V11
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin and dexamethasone, work in different ways to stop the growth of…
- Trial name
- NCT00814541
- Testing
- Bortezomib, Doxorubicin, Dexamethasone
- Where
- 9 sites in Ireland, United Kingdom
- Volunteers
- 53 people
- Sponsor
- Cancer Trials Ireland
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003331
- Testing
- fluorouracil, leucovorin calcium, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Waldenstrom's Macroglobulinemia
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
This research study is evaluating a drug called ixazomib (also known as MLN9708) in combination with dexamethasone and rituximab (the regimen is called IDR) as a possible treatment for Waldenstrom's Macroglobulinemia (WM).
- Trial name
- NCT02400437
- Testing
- Ixazomib, Dexamethasone, Rituximab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute
Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
This phase II trial studies how well donor atorvastatin treatment works in preventing severe graft-versus-host disease (GVHD) after nonmyeloablative peripheral blood stem cell (PBSC) transplant in patients with hematological…
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Lymphocytic Leukemia, Loss of Chromosome 17p
- Trial name
- NCT01527045
- Testing
- Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Fred Hutchinson Cancer Center
Waldenstrom Macroglobulinemia
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM).
- Trial name
- NCT05734495
- Testing
- Pirtobrutinib, Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
Study of Plitidepsin (Aplidin®) to determine the recommended dose (RD) of plitidepsin in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma.
- Trial name
- NCT02100657
- Testing
- Plitidepsin, Bortezomib, Dexamethasone
- Where
- 7 sites in France, Spain
- Volunteers
- 39 people
- Sponsor
- PharmaMar
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
This randomized phase III trial studies how well graft-vs-host disease (GVHD) prophylaxis works in treating patients with hematologic malignancies undergoing unrelated donor peripheral blood stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01231412
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 174 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
RATIONALE: Drugs such as melphalan, thalidomide, and dexamethasone may be effective in treating patients with primary systemic amyloidosis.
- Trial name
- NCT00089167
- Testing
- filgrastim, dexamethasone, melphalan
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thrombosis, Myocardial Infarction
Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients
The investigators will be comparing the effects of two different drug treatment strategies, in patients with history of a heart attack, on different markers of bleeding and clotting risk.
- Trial name
- DEFINE CCS (NCT05116995)
- Testing
- Rivaroxaban, Ticagrelor
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Nova Scotia Health Authority
Hemorrhoids
Comparison Study of Surgical Staplers for the Treatment of Hemorrhoids
The purpose of this study is to demonstrate that the Covidien EEA™ Hemorrhoid and Prolapse Stapling Set for the treatment of hemorrhoids is non-inferior to the competitor device based on the primary endpoint.
- Trial name
- HEMOSTASIS (NCT01306877)
- Testing
- EEA Hemorrhoid and Prolapse Stapling Set, Endosurgery Proximate PPH03 Stapling Set
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Medtronic - MITG
Waldenstrom Macroglobulinemia
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
The purpose of this study is to evaluate the efficacy and safety of daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated Waldenstrom macroglobulunemia (WM).
- Trial name
- THRiL for WM (NCT01779167)
- Testing
- Thalidomide, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma
A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma
To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with clofarabine.
- Trial name
- NCT00241371
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
This is an open label Phase II study to determine the rate of improvement in response of patients with previously treated multiple myeloma to imetelstat alone or in combination with lenalidomide maintenance therapy.
- Trial name
- NCT01242930
- Testing
- Imetelstat (7.5 mg/kg), lenalidomide standard of care, Imetelstat (9.4 mg/kg)
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Geron Corporation
Vascular Ehlers-Danlos Syndrome
Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients
Vascular Ehlers-Danlos Syndrome (VEDS) is caused by pathogenic variants of the COL3A1 gene, resulting abnormal Type III collagen protein.
- Trial name
- NCT05994664
- Testing
- Heartmath Intervention, Control Group
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Baylor College of Medicine
Multiple Myeloma (MM)
Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients
This prospective, non-interventional study aims to characterize the molecular and cellular mechanisms underlying the response and resistance of multiple myeloma (MM) patients to bispecific antibodies (BisAb) and CAR-T therapies.
- Trial name
- MMOMICS (NCT06888856)
- Volunteers
- 200 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Multiple Myeloma
Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)
After the KFDA (Korea Food and Drug Administration) approval of a new drug, an annual report of the drug's safety and efficacy data must be reported to the Health Authority in 6 years.
- Trial name
- NCT01005628
- Testing
- bortezomib
- Where
- South Korea
- Volunteers
- 1,121 people
- Sponsor
- Janssen Korea, Ltd., Korea
Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
This study will include participants with relapsed/refractory (R/R) Multiple Myeloma (MM). MM is a type of cancer of the blood. This study will also include participants with relapsed/refractory (R/R) Diffuse Large B-Cell…
- Conditions
- Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
- Trial name
- NCT05121103
- Testing
- EZM0414
- Where
- 8 sites in United States
- Volunteers
- 13 people
- Sponsor
- Epizyme, Inc.
Multiple Myeloma
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in monotherapy or combination with BMS-986405 in participants with relapsed and…
- Trial name
- NCT04036461
- Testing
- CC-99712, BMS-986405
- Where
- 20 sites in United States, Canada and 3 more
- Volunteers
- 47 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.